A group of over 50 healthcare providers, including physicians, nurses and physician assistants, have come together to demand the federal government stop any action that would restrict access to lifesaving medications through personal prescription importation.
In a letter sent to President Donald Trump, members of Congress and the Food and Drug Administration (FDA), the healthcare providers expressed their alarm over FDA’s action in Florida against offices that primarily serve older Americans who prefer in-person assistance with purchasing medications from Canada and other countries, rather than using an internet site. Last year, FDA agents armed with search warrants notified the office owners that importing drugs is illegal and those who help “administer” such drugs could face fines or jail time. Yet, according to its owners, these offices do not dispense or administer medication to patients. (more…)
Prescription Justice recently joined with nine other health, social justice and consumer advocacy organizations to launch a petition to demand Congress act to bring relief to the millions of Americans who can't afford the prescription drugs they need.
The online petition largely echoes the Prescription Justice policy platform which prioritizes ending the ban on Medicare negotiating drug prices, making pay-for-delay deals illegal, and permitting wider access to lower-cost, imported medication through legislative, regulatory, and policy reforms. (more…)
As we leave 2017 behind, the crisis of high prescription drug prices continues to threaten the health and well-being of Americans who struggle to access life-saving medications. Millions of Americans are forced to choose between taking the medicine they need, paying the rent or buying food for their families; tens of millions don't take prescribed medication; and federal and state budgets are overwhelmed. At Prescription Justice, we are dedicated solely to putting an end to this devastating crisis.
Over the past year, we have concentrated our efforts and resources on advocating for regulatory and legislative reforms and commonsense policies to lower domestic drug prices and expand access to lower cost medication from pharmacies in other countries. (more…)
Recently, The Hill featured the Op-Ed, A tale of two drug bills — one proposed bill will worsen the drug prices crisis, by Gabriel Levitt, President of Prescription Justice. Mr. Levitt’s Op-Ed provides an insightful look at legislation targeting two distinct public health problems, but only one has the capacity to inflict further devastation from the public health crisis that is high drug prices.
The Synthetics Trafficking & Overdose Prevention Act of 2017 (STOP Act), introduced by Sen. Rob Portman (R- OH) aims to stop the flow of the highly addictive synthetic opioid fentanyl from coming into the U.S. by requiring the U.S. Postal Service (USPS) to obtain information about packages coming from foreign sources. Unlike private carriers such as UPS and FedEx, the USPS does not currently require advanced electronic customs data from much of the mail received at its International Mail centers.
The Brussels Principles underscore the importance of the international online marketplace as a lifeline of affordable medication for the millions of people forced to go without necessary treatment due to drug cost and availability.
On March 31st, 2017, Prescription Justice organized a panel for the RightsCon 2017 conference in Brussels, which addressed protecting online access to safe and affordable medication. The organizers of RightsCon just published their outcomes document in which Prescription Justice’s effort to bring together both medicines access and Internet freedom advocates was recognized.
At that conference, the participants discussed a set of draft principles pertaining to medication sales over the Internet and prescription drug importation. The prevailing position among the panelists was that initiatives funded by the pharmaceutical industry that affect access to medicines on the Internet were detrimental to the cause of prescription drug affordability.
The U.S. Centers for Disease Control and Prevention (CDC) - Public Health Grand Rounds – recently hosted a webinar on “Overcoming Barriers to Medication Adherence for Chronic Diseases.”The event brought together a panel of leaders in pharmacy, nursing, medicine, academia, and public health to discuss the burden of medication nonadherence and barriers for adherence among patients with chronic diseases—including HIV/AIDS.
Medication nonadherence manifests in two distinct behaviors: intentional, such as choosing to forgo filling a prescription because of cost, or unintentional, where patients simply forget to take their medication or are unable to manage multiple medications or complex treatment regimens. The panelists highlighted how intervention strategies aimed at medication adherence can positively affect patient health outcomes. (more…)
We are proud to announce that we have changed our organization's (DBA) name from Prescription Justice Action Group to Prescription Justice, which is a simpler expression of our core position: making prescription drugs affordable is an issue of justice for Americans and we will help them obtain it.
In addition to our website and logo redesign, we have also added a weekly media update that features top news and journal articles focused on our policy priorities - personal drug importation, Medicare Drug Price Negotiations, and ending "Pay for Delay", - as well as other advocacy efforts about tackling the prescription drug price crisis in America and globally.
Let's all work together to bring about prescription justice!
The pharmaceutical industry often defends shameful price gouging of consumers by arguing that their high profits fund the research and development of tomorrow’s new miracle cures. There is robust debate about the degree to which lowering drug prices would hurt pharmaceutical innovation. The current system holds consumers and governments hostage to pharmaceutical company business models in a manner that is inherently unethical. Think of the cancer patient who has to shell out $30,000 in co-insurance to live, and if not, then die.
The concept and practice of “delinkage,” in which the invention of new medicines is delinked from high drug prices transcends this old debate and envisions a brighter more humane future…one with robust pharmaceutical innovation.
Part of a series of posts about common chronic illnesses and what happens when people cannot afford prescription medications to treat them.
Hepatitis C is an infection caused by a virus that attacks the liver and causes inflammation. An estimated 3.5 million Americans are living with hepatitis C, with about half unaware they even have it. Recent advancements in hepatitis C treatments have greatly improved. New medications can lead to a cure in about 90 percent of people. But the prices for such treatments are prohibiting access and that means more people will remain sick and sometimes die. The Centers for Disease Control and Prevention found that in 2014, hepatitis C related deaths reached an all-time high of 19,659, killing more Americans each year than all other infectious diseases combined, including HIV.